Quantcast

Latest Actavis Stories

2014-02-28 08:25:23

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq(®), which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of...

2014-02-27 12:27:03

CHICAGO, Feb. 27, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dr. Reddy's Laboratories Ltd. (NYSE:RDY-Free Report), Actavis plc (NYSE:ACT-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report), Biogen Idec Inc. (Nasdaq:BIIB-Free Report) and eBay Inc. (Nasdaq:EBAY-Free...

2014-02-26 08:27:54

BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Wednesday, March 5, 2014 Time: 8:30...

2014-02-20 08:29:17

- Fourth Quarter 2013 GAAP Loss Per Share of $0.86 - DUBLIN, Feb. 20, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 59 percent to $2.779 billion for the fourth quarter ended December 31, 2013, compared to $1.75 billion in the fourth quarter 2012. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2013 increased to $3.17, compared to $1.59 per diluted share in the fourth quarter 2012. GAAP loss per share for the fourth...

2014-02-19 16:25:03

DUBLIN, Feb. 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at Citi's 2014 Global Healthcare Conference in New York. The presentation will take place on Tuesday, February 25, 2014 at 2:40 PM Eastern Standard Time at the Hilton New York Hotel, 1335 Avenue of the Americas, New York, New York. To access a...

2014-02-18 16:26:50

DUBLIN, Feb. 18, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to issue its fourth quarter and full-year 2013 earnings release as planned on Thursday, February 20, 2014, prior to the opening of the U.S. markets. However, following the Company's announcement earlier today regarding its proposed acquisition of Forest Laboratories, Inc., Actavis has elected not to conduct an earnings conference call to discuss the quarterly and full-year results. The...

2014-02-18 08:30:08

- Creates an Innovative New Model in Specialty Pharmaceuticals Leadership, with $15 Billion in Revenue and a Growing ~$7 Billion North American Specialty Brand Business - DUBLIN, Ireland and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest...

2014-02-11 08:32:16

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) announced today that it intends to release fourth quarter 2013 financial results on Thursday, February 20, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 20, 2014 to discuss its financial results. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and the Conference ID...

2014-02-04 08:34:45

DUBLIN, Feb. 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial. Actavis' ANDA product is a generic version of Cephalon's Treanda(®), a treatment for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Cephalon, Inc. filed suit against Actavis on January 31,...

2014-01-31 08:24:59

- 2014 Revenue forecast to be $10+ Billion - DUBLIN, Jan. 31, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today provided a detailed look into the company's newly restructured global commercial operations, expanded pipeline and outlook for continued long-term growth during its fifth annual Investor Meeting in New York. In conjunction with the meeting, the Company reiterated that it expects 2013 non-GAAP earnings per diluted share to be...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related